MedTrace Logo

Combining Chemoradiotherapy With Sintilimab in First-Line ICC

NCT06447454 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 19

Last updated 2024-06-07

No results posted yet for this study

Summary

To evaluate the effectiveness and safety of GC (gemcitabine + cisplatin) and radiotherapy combined with slulimumab in the treatment of first-line intrahepatic cholangiocarcinoma patients

Conditions

  • ICC

Interventions

RADIATION

radiotherapy

radiotherapy

DRUG

gemcitabine + cisplatin

Gemcitabine 1000mg/m² intravenous infusion over 30 minutes, cisplatin 25mg/m² intravenous infusion, on day 1 and day 8, every 3 weeks.

DRUG

slulimumab

Slulimumab, 4.5mg/kg intravenous infusion, Q3W

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    lead OTHER

Principal Investigators

  • Shisuo Du · Fudan University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-01
Primary Completion
2026-12-31
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06447454 on ClinicalTrials.gov